Milestone Pharmaceuticals Inc. (MIST) Form 8-K — Oct 28, 2026
Milestone Pharmaceuticals received a Nasdaq deficiency notice on October 23, 2026 because its share price traded below $1.00 for 30 consecutive business days, breaching Listing Rule 5450(a)(1). The company has 180 days, until April 21, 2027, to close at $1.00 or higher for 10 consecutive business days to regain compliance. It may also transfer to the Nasdaq Capital Market for additional time, possibly via a reverse stock split. The notice has no immediate effect on the listing, but failure to cure could lead to delisting.
Key figures
- Compliance deadline
- April 21, 2027
- Compliance period days
- 180
- Transfer application fee usd
- 5000
- Consecutive days required at 1usd
- 10
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.